<DOC>
	<DOCNO>NCT02699749</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , pharmacokinetics ( PK ) , maximum tolerate dose ( MTD ) TAK-931 participant advance nonhematologic tumor .</brief_summary>
	<brief_title>A Study Evaluate TAK-931 Participants With Advanced Nonhematologic Tumors</brief_title>
	<detailed_description>The drug investigation study call TAK-931 . The effect TAK-931 evaluate 100 participant nonhematologic ( solid ) neoplasms . This study look safety , tolerability , PK determine maximum tolerate dose ( MTD ) TAK-931 . This multi-center trial conduct Japan . The overall study duration approximately 42 month total dose escalation cohort safety expansion cohort . Participants make multiple visit clinic final visit approximately 30-40 day last dose study drug follow-up assessment .</detailed_description>
	<criteria>1 . Must advance , nonhematologic solid tumor . 2 . Must eastern cooperative oncology group ( ECOG ) performance status 0 1 . 3 . Must life expectancy great equal ( &gt; = ) 3 month . 4 . Must ability swallow oral medication , willingness undergo serial skin punch biopsy , suitable venous access studyrequired PK pharmacodynamic sampling . 5 . Must adequate bone marrow , liver , kidney cardiac function 1 . Must serious uncontrolled medical disorder . 2 . Must medication may interfere absorption excretion TAK931 3 . Must medication affect normal cardiac blood pressure response . 4 . Must uncontrolled significant cardiovascular disease , hypertension hypotension .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>